CAR-T Therapy in Leukemia: Limitations and Prospects
In the broad field of cancer management via immunotherapy, chimeric antigen receptor T-cell therapy (CAR-T therapy), commonly known as CAR-T therapy, has become a game-changing approach, particularly for patients with relapsed or refractory lymphoma. Using genetic engineering, a patient's T cells can be genetically mod...